1. Home
  2. CGEM vs CHI Comparison

CGEM vs CHI Comparison

Compare CGEM & CHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$13.77

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo Calamos Convertible Opportunities and Income Fund

CHI

Calamos Convertible Opportunities and Income Fund

HOLD

Current Price

$12.45

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
CHI
Founded
2016
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
1.0B
IPO Year
2020
2002

Fundamental Metrics

Financial Performance
Metric
CGEM
CHI
Price
$13.77
$12.45
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$30.13
N/A
AVG Volume (30 Days)
881.8K
169.6K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
9.90%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$10.00
52 Week High
$16.74
$12.70

Technical Indicators

Market Signals
Indicator
CGEM
CHI
Relative Strength Index (RSI) 42.75 59.12
Support Level $12.41 $10.34
Resistance Level $16.21 $12.70
Average True Range (ATR) 0.94 0.26
MACD -0.16 -0.04
Stochastic Oscillator 11.57 78.26

Price Performance

Historical Comparison
CGEM
CHI

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About CHI Calamos Convertible Opportunities and Income Fund

CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.

Share on Social Networks: